Massively parallelized cell line engineering platform that accelerates manufacturing of gene and cell therapies.
VectorSelect is 64x Bio's core platform that combines massively parallel screens with computational insights to engineer high-yield cell lines and production technologies for advanced therapeutics. The platform powers three product suites: AAV Apex Suite for high-yield AAV gene therapy production, LV Apex Suite for lentiviral vector production supporting CAR-T programs, and Next Apex Suite for biologics including antibodies. Partners license high-performing cell lines through these Apex Suites or use VectorSelect for flexible cell line optimization. VectorSelect is a product of 64x Bio.